U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07556471) titled 'Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo' on April 16.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo.
Drawing on the prior/preclinical data of LW402 tablets, this clinical trial will incorporate three dose groups: 50 mg twice daily (BID), 100 mg BID, and 150 mg BID. The trial will be structured into a screening period (maximum 5 weeks), a treatment period (52 weeks, encompassing a 24-week main trial p...